Silo Pharma develops novel therapeutics and drug-delivery systems for stress-induced psychiatric disorders, chronic pain and central nervous system diseases, while also disclosing activity in cryptocurrency treasury and AI infrastructure initiatives. Company news frequently centers on SPC-15, an intranasal serotonin 5-HT4 receptor agonist program for PTSD and anxiety, as well as other pipeline work involving psychedelic-derived and traditional therapeutic approaches.
Recurring updates include patent allowances and applications in key jurisdictions, FDA and federal-policy context for psychedelic medicines, clinical-development planning, and new CNS discovery initiatives such as ibogaine-based approaches for traumatic brain injury. Corporate news also covers common-stock repurchase authorization, equity-financed asset purchases, the QwikAgents AI-agent platform, and cryptocurrency-related software assets.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Silo Pharma, a biopharmaceutical company focusing on psychedelic research, announced that James Kuo, M.D., will present at the 3rd Annual Psychedelic Therapeutics and Drug Development Conference on May 15-16, 2023, in Burlingame, CA. Dr. Kuo's presentation, titled ‘The Ketamine Endgame,’ will explore the potential of ketamine for treating conditions like treatment-resistant depression, anxiety, and pain. Three of the company's drug candidates utilize ketamine: SP-26 for fibromyalgia, SPC-14 for Alzheimer's-related dementia, and SPC-15 for stress and PTSD. The conference aims to discuss challenges and advancements in psychedelic research for various health conditions including depression, PTSD, and pain management.
Silo Pharma (Nasdaq:SILO) has announced the development of SPC-15, a novel drug formulation targeting stress, anxiety, and PTSD. This initiative is part of a research agreement with Columbia University and aims to explore dose strengths and delivery methods for this potential treatment. Current research suggests that SPC-15 could effectively address cognitive impairment and other stress-related disorders. The drug's development aligns with alarming statistics: over 300 million people globally suffer from anxiety disorders, while approximately 12 million U.S. adults experience PTSD. The market for anxiety and depression treatments is projected to reach $13 billion by 2027. Additionally, Silo Pharma has secured a U.S. patent for SPC-15 as a treatment method for stress-induced disorders in females.